COST-EFFECTIVENESS OF ONCE-WEEKLY SEMAGLUTIDE 1 MG VS. CANAGLIFLOZIN 300 MG IN PATIENTS WITH TYPE 2 DIABETES IN A CANADIAN SETTING

被引：0
|
作者：
Liu, A. [1 ]
Bech, P. [1 ]
Fridhammar, A. [2 ]
Nilsson, A. [2 ]
Willis, M. [2 ]
Johansen, P. [3 ]
机构：
[1] Novo Nordisk Canada Inc, Mississauga, ON, Canada
[2] Swedish Inst Hlth Econ, Lund, Sweden
[3] Novo Nordisk AS, Soborg, Denmark
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB32
引用
收藏
页码：S114 / S114
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
    Sara Stafford
    Peter G. Bech
    Adam Fridhammar
    Nino Miresashvili
    Andreas Nilsson
    Michael Willis
    Aiden Liu
    [J]. Applied Health Economics and Health Policy, 2022, 20 : 543 - 555
  • [2] Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
    Stafford, Sara
    Bech, Peter G.
    Fridhammar, Adam
    Miresashvili, Nino
    Nilsson, Andreas
    Willis, Michael
    Liu, Aiden
    [J]. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2022, 20 (04) : 543 - 555
  • [3] Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
    Sara Stafford
    Peter G. Bech
    Adam Fridhammar
    Nino Miresashvili
    Andreas Nilsson
    Michael Willis
    Aiden Liu
    [J]. Applied Health Economics and Health Policy, 2022, 20 : 623 - 623
  • [4] EVALUATING THE COST-EFFECTIVENESS OF ONCE-WEEKLY SEMAGLUTIDE 1 MG VERSUS EMPAGLIFLOZIN 25 MG FOR TREATMENT OF PATIENTS WITH TYPE 2 DIABETES IN THE UK SETTING
    Capehorn, M.
    Hallen, N.
    Hunt, B.
    [J]. VALUE IN HEALTH, 2020, 23 : S512 - S512
  • [5] Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting
    Matthew Capehorn
    Nino Hallén
    James Baker-Knight
    Divina Glah
    Barnaby Hunt
    [J]. Diabetes Therapy, 2021, 12 : 537 - 555
  • [6] Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting
    Capehorn, Matthew
    Hallen, Nino
    Baker-Knight, James
    Glah, Divina
    Hunt, Barnaby
    [J]. DIABETES THERAPY, 2021, 12 (02) : 537 - 555
  • [7] Cost-Effectiveness of Once-Weekly Semaglutide 1.0 mg vs. Dulaglutide 1.5 mg as Add-On to Metformin in the Treatment of Type 2 Diabetes in Canada
    Johansen, Pierre
    Hakan-Bloch, Jonas
    Liu, Aiden R.
    Persson, Sofie
    Grip, Emilie Toresson
    [J]. DIABETES, 2018, 67
  • [8] The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK
    Adie Viljoen
    Barrie Chubb
    Samuel J. P. Malkin
    Sasha Berry
    Barnaby Hunt
    Stephen C. Bain
    [J]. The European Journal of Health Economics, 2023, 24 : 895 - 907
  • [9] The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK
    Viljoen, Adie
    Chubb, Barrie
    Malkin, Samuel J. P.
    Berry, Sasha
    Hunt, Barnaby
    Bain, Stephen C.
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2023, 24 (06): : 895 - 907
  • [10] Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting (Mar, 10.1007/s40258-022-00726-z, 2022)
    Stafford, Sara
    Bech, Peter G.
    Fridhammar, Adam
    Miresashvili, Nino
    Nilsson, Andreas
    Willis, Michael
    Liu, Aiden
    [J]. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2022, 20 (04) : 623 - 623
12345